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Elsevier Taiwan LLC. Open access under CSummary Background: Hepatocellular carcinoma is a common cancer with an increasing inci-
dence worldwide because of the dissemination of hepatitis B and hepatitis C virus infection. Sur-
gical resection is the most important therapeutic option with a curative intent. Early tumor
detection through screening and improvements in surgical techniques have significantly improved
the outcome of patients with hepatocellular carcinoma. However, local recurrence after curative
hepatic resection is common and is the most frequent cause of death in these patients.
Patients andMethods: In anattempt to identify the risk factors that predict tumor recurrence,we
conducted this retrospective study in a single institution for a 6-year period. Of the 100 consecu-
tive patients who underwent curative tumor resection, we analyzed age, sex, viral etiology (hep-
atitis B virus vs. hepatitis C virus), preoperative levels of aspartate aminotransferase and alanine
aminotransferase, the a-fetoprotein level, underlying liver disease status (chronic hepatitis vs.
cirrhosis), number and size of tumors, type of resection, and presence of microvascular invasion.
Results: In the median follow-up period of 36 months (range, 12e85 months), the 1-year, 3-year,
and 5-year overall survival rateswere 90%, 84%, and73%, respectively; tumor recurrence occurred
in 38 (38%) patients and was the leading cause of death among the patients who died (15 of 17 pa-
tients; 88%).Onunivariateanalysis, theonly factor significantly associatedwithahigher incidence
of tumor recurrencewaspreoperative levels of aspartateaminotransferase greater than twice the
upper normal value (p< 0.01) and this factor remained significantwithmultivariate analysis. Sub-
group analysis of the risk factor of early tumor recurrence (2 years) and late tumor recurrenceastroenterology and Hepatology, Department of Internal Medicine, Chi-Mei Medical Center, Number
a, Tainan 710, Taiwan.
4.01.003
stroenterological Society of Taiwan and The Digestive Endoscopy Society of Taiwan. Published by
C BY-NC-ND license.
Predictors of hepatocellular carcinoma recurrence 15(>2 years)was conducted andapreoperative aspartate aminotransferase level greater than twice
the upper normal value was still significant in both groups (pZ 0.02 and pZ 0.044, respectively).
Conclusion: Although this is a small-scale study, our findings could be easily applied clinically and
used as readily available indicators to help the follow-up algorithm.Wealso suggest antiviralman-
agementas soonaspossible for patientswithhepatocellular carcinomaundergoingcurative resec-
tion, especially those with a high preoperative aspartate aminotransferase level.
Copyrightª 2014, TheGastroenterological Society of Taiwan andTheDigestive Endoscopy Society
of Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.Table 1 Clinicopathological features of patients in this
study.
Variable n (%)
Sex
Male 69 (69)
Female 31 (31)
Etiology of liver disease
Hepatitis B 52 (52)
Hepatitis C 32 (32)
Hepatitis B þ C 6 (6)
Alcohol 7 (7)
Other 3 (3)
Non-neoplastic liver disease
Liver cirrhosis 79 (79)
Chronic hepatitis 21 (21)
Diameter of main nodule (cm)
<3 51 (51)
3 26 (26)
5 23 (23)
Number of nodules
Single 91 (91)
Multiple 9 (9)
BCLC stage
Stage 0 25 (25)
Stage A 59 (59)
Stage B 16 (16)
Microvascular invasion
Positive 2 (2)
Negative 98 (98)
BCLC Z Barcelona Clinic Liver Cancer classification.Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers in Asia and Africa and its incidence is increasing
worldwide because of the dissemination of hepatitis B virus
(HBV) and hepatitis C virus (HCV) infection [1]. It is prevalent
in Taiwan with around 10,000 new cases each year and has
been the leading cause of cancer death, accounting for
approximately 8000 deaths annually [2]. Recent advances in
screening, such as ultrasonography, dynamic computed to-
mography, and magnetic resonance imaging, have made
early diagnosis possible and thus improved survival [3,4].
Surgery is the most important therapeutic option for patients
with HCC [5,6]. With the progress in early diagnosis and
operative techniques, the outcome of patients with HCC
after tumor resection have significantly improved, with
median survival rates of 80% (range, 63e97%) at 1 year and
50% (range, 17e69%) at 5 years, with a surgical mortality
rate of less than 2% [5,7e9]. The wide ranges of survival
rates are attributed mainly to differences in the HCC stage
among various studies, with an obvious survival advantage in
early-stage tumors [10]. However, a significant proportion of
patients cannot achieve a cure or a sustained tumor-free
survival and the long-term outcome after initial treatment
remains unsatisfactory because of a high recurrence rate,
ranging from 43% to 100% at 5 years [6,7,11e15].
HCC recurrence has been classified as early (within 2e3
years) or late. Early recurrence is usually due to metastasis
from the primary tumor (dissemination from the primary
tumor), whereas late recurrence is often due to de novo
second primary tumors occurring in a cirrhotic or HBV-
infected liver [16]. Many factors have been identified to
be associated with tumor recurrence after surgical resec-
tion, including: the accompanying chronic viral hepatitis
status (Ishak activity score); serum levels of albumin,
aspartate aminotransferase (AST), alanine aminotrans-
ferase (ALT), a-fetoprotein, and HBV DNA; the extent of
hepatectomy; and various tumor factors [12,13,16e21].
Among these, the most powerful predictors of recurrence
are the presence of microvascular invasion or additional
tumor sites besides the primary lesions, or both [12]. In this
retrospective study we aimed to identify the risk factors for
recurrence in patients undergoing curative surgical resec-
tion in a single institution.
Methods
We retrospectively searched the database of the Chi-Mei
Medical Center in southern Taiwan for patients diagnosedwith HCC who underwent curative liver resection from
March 2002 to March 2008. The institutional review board
approved this study. We used either ultrasonography and
abdominal computed tomography (CT) scan or magnetic
resonance imaging (MRI) to determine the anatomical
location of HCC; the operative procedures were defined
according to Couinaud’s classification of hepatic segments
[22]. Curative resection referred to a complete resection of
all macroscopic tumors with tumor clearance along the
parenchymal transection line.
We reviewed the medical records of the patients for the
underlying causes of hepatitis and coexisting liver diseases.
Those patients with cirrhosis were classified according to
the ChildePugh scheme [23]. The clinicopathological vari-
ables evaluated included age at surgery, sex, etiology of
hepatitis, a-fetoprotein level, microvascular invasion,
Table 2 Univariate analysis of disease-free survival.
Variable Recurrence of HCC (n Z 38) D
Age (y) 56.4  10.6 59
Male sex 30 (78.9) 39
Etiology of liver disease
Hepatitis B 21 (55.3) 31
Hepatitis C 13 (34.2) 19
Hepatitis B þ C 2 (5.3) 4
AST > 1N 27 (71.1) 35
ALT > 1N 30 (78.9) 41
AST > 2N 15 (39.5) 10
ALT > 2N 16 (42.1) 16
Liver cirrhosis 33 (86.8) 46
Liver nodules number
Single 34 (89.5) 57
Multiple 4 (10.5) 5
Diameter of nodule (cm)
<3 18 (47.4) 33
3 9 (23.7) 17
5 11 (28.9) 12
BCLC stage
Stage 0 8 (21.1) 17
Stage A 21 (55.3) 38
Stage B 9 (23.7) 7
AFP > 20 18 (47.4) 27
Data are presented as n (%) or mean  SD.
1N Z greater than the upper normal value; 2N Z greater than twic
aminotransferase; AST Z aspartate aminotransferase; BCLC Z Barce
HCC Z hepatocellular carcinoma; HR Z hazard ratio.
Figure 1 Survival curves for patients with hepatocellular
carcinoma who underwent curative surgical resection with and
without recurrence.
16 K.-M. Chung et al.number and size of tumors, type of resection, underlying
liver disease status (chronic hepatitis vs. cirrhosis), and
preoperative levels of AST and ALT. The Barcelona Clinic
Liver Cancer (BCLC) classification was used for clinical
staging. All patients were followed up regularly every 2e3
months after surgery. Tumor recurrence was suspected in
the presence of progressive elevation of serum a-fetopro-
tein levels and detection of a new hepatic lesion by ultra-
sonography. Tumor recurrence was diagnosed by dynamic
CT scan or MRI showing contrast enhancement during the
arterial phase and washout in the venous phase, or hepatic
angiography disclosing a high vascularity tumor. Once
tumor recurrence was suspected, patients were admitted
to hospital for the confirmation of diagnosis and appro-
priate management, including resection, local ablation
treatment, transcatheter arterial chemoembolization,
chemotherapy, radiotherapy, or supportive treatment.
Continuous data were expressed as mean  standard
deviation and compared with the unpaired t test. Dichot-
omous variables were evaluated with c2 analysis or Fisher’s
exact test to define various patient groups contributing
significantly to the factors affecting disease-free survival
and recurrence. Survival analysis was performed by the
KaplaneMeier method and the difference in the curves was
tested with the log-rank test. To determine prognostic
factors for disease-free survival during the follow-up
period, the Cox proportional hazard model was used to
estimate the risk of the following potential variables: age,
sex, viral etiology (HBV or HCV), a-fetoprotein level, num-
ber and size of tumors, type of resection, underlying liverisease-free survival (n Z 62) HR (95% CI) p
.3  11.6 0.22
(62.9) 1.76 (0.88e3.52) 0.092
(50.0) 1.12 (0.73e1.72) 0.609
(30.6) 1.05 (0.79e1.40) 0.711
(6.5) 0.98 (0.89e1.10) 0.808
(56.5) 1.50 (0.85e2.67) 0.144
(66.1) 1.61 (0.79e3.21) 0.17
(16.1) 1.39 (1.05e1.83) 0.009
(25.8) 1.28 (0.94e1.74) 0.09
(74.2) 1.97 (0.76e6.89) 0.132
0.676
(91.9)
(8.1)
0.541
(53.2)
(27.4)
(19.4)
0.248
(27.4)
(61.3)
(11.3)
(43.5) 0.92 (0.59e1.43) 0.709
e the upper normal value; AFP Z a-fetoprotein; ALT Z alanine
lona Clinic Liver Cancer classification; CI Z confidence interval;
Predictors of hepatocellular carcinoma recurrence 17disease status (chronic hepatitis, cirrhosis), and preopera-
tive levels of AST and ALT. After univariate analysis, only
those variables that reached p < 0.05 were used in the
multivariate analysis. The multivariable Cox proportional
hazard model was built by stepwise variable with entry and
removal exit criteria set at p Z 0.05 and p Z 0.1,
respectively. Statistical significance was set at p < 0.05.
SPSS version 19.0 (SPSS Inc., Chicago, IL, USA) was used for
all statistical analyses.Figure 2 (A) Impact of preoperative aspartate aminotrans-
ferase (AST) levels greater than twice normal values on the risk
of local recurrence. (B) Impact of preoperative alanine
aminotransferase (ALT) levels greater than twice normal on the
risk of local recurrence. 2N Z greater than twice the upper
normal value.Results
We identified a total of 113 patients receiving curative
resection for HCC during this study period; 13 patients had
data missing, but the remaining 100 patients were
analyzed in this study. Table 1 summarizes the clinico-
pathological characteristics of the patients. There were
69 men and 31 women with a median age of 59.5 years
(range, 52e66 years). Sixteen patients were 70 years or
older. Twenty-one patients had chronic hepatitis; 79 had
liver cirrhosis according to pathological findings, all
ChildePugh class A. The underlying causes of disease were
HBV and HCV in 52% and 32% of patients, respectively,
whereas coinfection of HBV and HCV occurred in 6%. The
remaining cases included 7% of patients with alcoholic
liver disease and 3% with other unidentified causes. The
hepatic tumors were single in 91 (91%) patients and mul-
tiple in the remaining 9 (9%) patients. The median diam-
eter of the largest tumor in each patient was 4.7 cm
(range, 1e11 cm). Twenty-six patients were BCLC stage 0,
58 patients were stage A, and the remaining 16 patients
were stage B. Seventy-six patients underwent segmen-
tectomy and the remaining 24 underwent major hepa-
tectomy. Microvascular invasion was identified by
pathological findings in only two (2%) patients. The me-
dian follow-up time was 36 months (range, 12e85
months). The 1-year, 3-year, and 5-year overall survival
rates were 90%, 84%, and 73%, respectively.
Tumor recurrence occurred in 38 (38%) patients.
Seventeen patients died during the follow-up period and
the causes of death included tumor recurrence (15 pa-
tients, 88%) and one patient (6%) each with intracranial
hemorrhage and operative complications. The 1-year, 3-
year, and 5-year disease-free survival rates were 77.5%,
61.1%, and 48.6%, respectively. The survival rate between
the disease-free and tumor recurrence groups was signifi-
cant (p < 0.001; Fig. 1).
On univariate analysis, the only factor significantly
associated with a higher incidence of tumor recurrence was
preoperative levels of AST greater than twice the upper
normal value (2N; p < 0.01). Tumor recurrence was not
related to age at surgery, sex, or HBV or HCV infection, a-
fetoprotein level, tumor size (<3 cm, 3e5 cm, or >5 cm),
tumor multifocality (single vs. multiple), type of resection,
underlying chronic hepatitis versus cirrhosis, or preopera-
tive levels of ALT greater than twice the normal value
(Table 2). Preoperative AST level greater than twice the
normal value remained significantly (p < 0.05) related to a
higher incidence of tumor recurrence with multivariate
analysis. Meanwhile, patients with preoperative levels of
AST and ALT greater than twice the upper normal value had
Table 3 Risk factor analysis of no recurrence and early recurrence of hepatocellular carcinoma.
Variable No recurrence (n Z 62) Recurrence 2 y (n Z 32) RR (95% CI) p
Male sex 39 (62.9) 28 (87.5) 1.98 (0.89e4.36) 0.068
Etiology of liver disease
Hepatitis B 31 (50.0) 20 (62.5) 0.80 (0.56e1.15) 0.249
Hepatitis C 19 (30.6) 8 (25.0) 1.23 (0.60e2.49) 0.567
Hepatitis B þ C 4 (6.5) 2 (6.3) 1.03 (0.20e5.34) 0.97
AST > 1N 35 (56.5) 22 (68.8) 0.82 (0.59e1.13) 0.247
ALT > 1N 41 (66.1) 25 (78.1) 0.85 (0.66e1.10) 0.228
AST > 2N 10 (16.1) 12 (37.5) 0.43 (0.21e0.89) 0.02
ALT > 2N 16 (25.8) 14 (43.8) 0.60 (0.33e1.10) 0.077
Liver cirrhosis 46 (74.2) 27 (84.5) 0.88 (0.71e1.08) 0.261
AFP > 20 27 (43.5) 15 (46.9) 0.93 (0.58e1.48) 0.759
1N Z greater than the upper normal value; 2N Z greater than twice the upper normal value; AFP Z a-fetoprotein; ALT Z alanine
aminotransferase; AST Z aspartate aminotransferase; CI Z confidence interval; RR Z relative risk.
18 K.-M. Chung et al.a higher cumulative proportion of local recurrence with
statistical significance (2N; p Z 0.023 and p Z 0.042,
respectively; Fig. 2A and B). In addition, subgroup analysis
was conducted to determine the risk factor of early tumor
recurrence (2 years; 32 patients, 84%) and late tumor
recurrence (>2 years; 6 patients, 16% ) in this study. A
significant correlation of high AST level and tumor recur-
rence, in both early and late recurrence, was noted, as
shown in Tables 3 and 4.Discussion
The overall survival after liver resection for patients with
HCC has been prolonged because of improvements in the
early detection of tumors and advances in surgical tech-
niques and perioperative care [3,4,6]. However, the long-
term results are not satisfactory as a result of tumor recur-
rence, which is the main cause of mortality [11,16,24,25].
Previous studies have identified that various factors, such as
tumor factors and a-fetoprotein levels, are related to a high
incidence of tumor recurrence [11,13,17,18,24,26]. In our
study, tumor recurrence occurred in 38% of patients and it
was the leading cause of death. Both univariate andTable 4 Risk factor analysis for no recurrence and late recurre
Variable No recurrence (n Z 62) Recur
Male 39 (62.9) 2 (33.
Etiology of liver disease
Hepatitis B 31 (50.0) 1 (16.
Hepatitis C 19 (30.6) 5 (83.
Hepatitis B þ C 4 (6.5) 0 (0.0
AST > 1N 35 (56.5) 5 (83.
ALT > 1N 41 (66.1) 5 (83.
AST > 2N 10 (16.1) 3 (50.
ALT > 2N 16 (25.8) 2 (33.
Liver cirrhosis 46 (74.2) 6 (100
AFP > 20 27 (43.5) 3 (50.
1N Z greater than the upper normal value; 2N Z greater than twic
aminotransferase; AST Z aspartate aminotransferase; CI Z confidenmultivariate analysis showed that preoperative levels of AST
greater than twice the normal value was the only factor
significantly associated with a higher rate of tumor recur-
rence after curative surgery.
Several Japanese groups have pointed out that chronic
active hepatitis and cirrhosis were the most significant risk
factors for intrahepatic tumor recurrence, which probably
develops through multicentric hepatocarcinogenesis, the
so-called “multicentric occurrence” after hepatectomy
[17,18,27]. This can be explained by the fact that repeated
inflammation and cellular necrosis in patients with chronic
hepatitis or cirrhosis enhance proliferating activity and
accelerate the development of new foci of HCC through an
increased rate of random mutations and promotion due to
gene instability [28,29]. Adachi et al [13] considered active
inflammation as a basic cause of recurrence. They found
that in livers with inflammatory changes, some adhesion
molecules that adhered to cancer cells in the remnant liver
after resection appeared and caused postoperative recur-
rence [13]. In patients with chronic hepatitis or cirrhosis,
the serum aminotransferase levels are usually considered
an index of inflammatory activity that reflects the etiopa-
thogenetic mechanism of hepatocytic necrosis [30]. In
keeping with these findings, we found that an elevatednce of hepatocellular carcinoma.
rence >2 y (n Z 6) RR (95% CI) p
3) 1.89 (0.60e5.95) 0.158
7) 3.00 (0.49e18.27) 0.118
3) 1.84 (0.58e5.80) 0.184
) 1.06 (0.99e1.14) 0.521
3) 0.68 (0.45e1.03) 0.201
3) 0.79 (0.53e1.18) 0.39
0) 0.32 (0.12e0.86) 0.044
3) 0.77 (0.23e2.60) 0.69
.0) 0.74 (0.64e0.86) 0.155
0) 0.87 (0.37e2.03) 0.761
e the upper normal value; AFP Z a-fetoprotein; ALT Z alanine
ce interval; RR Z relative risk.
Predictors of hepatocellular carcinoma recurrence 19preoperative AST level over twice upper normal values
(>2N) was the only variable closely associated with tumor
recurrence. In a cohort of 244 liver resections for HCC in
cirrhosis, Ercolani et al [7] identified that single nodules
and preoperative AST levels less than twice the upper
normal value (<2N) were related to a better 5-year disease-
free survival and lower tumor recurrence. In particular,
among HCV-positive patients the recurrence rate was
strongly affected by the preoperative AST level [7].
Similar results on the significance of elevated serum
aminotransferase levels predicting a higher chance of
recurrence, including in patients with small HCC, have also
been reported by other workers [9,17,31]. These data
indicate an important pathogenetic role of hepatic
inflammation and the patients with a higher risk of recur-
rence may benefit from adjuvant treatments with anti-
inflammatory drugs to prevent tumor recurrence after
liver resection. For these reasons, several workers have
investigated the efficacy of interferon, an inflammation-
modulating drug, for preventing the occurrence of HCC in
patients with HBV- or HCV-related liver disease [26,32,33].
Antiviral treatment with interferon has been recom-
mended to prevent tumor recurrence after primary cura-
tive treatments in HCV-related HCC [5]. However, there
was less evidence for antiviral treatment with nucleos(t)ide
analogues to prevent tumor recurrence in HBV-related HCC
[34]. The major reason for this phenomenon is that early
recurrence is probably due to previously undiscovered
metastasis from the primary tumor. The early recurrence
accounts for most of the total number of recurrences [35].
However, a recent retrospective analysis showed a favor-
able result on the 1-year, 3-year, and 5-year disease-free
survival rates in the early antiviral treatment group
compared with those without treatment [36]. Su et al [37]
also reported that antiviral treatment could decrease
recurrence in patients with HBV-induced HCC after resec-
tion surgery. Our result of high preoperative ALT levels
correlating with both early and late recurrences also sup-
ports the view that early antiviral treatment may
contribute to the survival of patients with HCC after cura-
tive treatment, especially for those with hepatitis activity.
A limitation of our study is the small number of patients,
especially when they are subdivided into three groups
based on tumor size and the underlying viral etiologies or
different age groups. Nonetheless, we identified a signifi-
cant correlation of high AST level and tumor recurrence in
both early and late recurrence. Our findings also suggest
that early antiviral treatment may improve the prognosis of
HBV-related HCC.Conflicts of interest
All contributing authors declare no conflicts of interest.References
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